Boehringer Ingelheim has
confirmed the sale of its US-based
Roxane Laboratories specialty
generics operation to Hikma
Pharmaceuticals, in a deal worth
US$2.65 billion in cash and shares.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 29 Jul 15 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 15
SIGMA Healthcare ceo Mark Hooper yesterday confirmed the company was “starting to see a return to growth in our brand member pipeline,” but said general trading conditions have continued to be challenging in the last quarter.